Next Article in Journal
Evidence for the Involvement of the Master Transcription Factor NF-κB in Cancer Initiation and Progression
Next Article in Special Issue
Comment on Khanal et al. The Repertoire of Adenovirus in Human Disease: The Innocuous to the Deadly. Biomedicines 2018, 6, 30
Previous Article in Journal
GABA Levels in Left and Right Sensorimotor Cortex Correlate across Individuals
Previous Article in Special Issue
Oncolytic Adenoviruses in Gastrointestinal Cancers
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview

Progress in Adenoviral Capsid-Display Vaccines

Janssen Infectious Diseases and Vaccines, Pharmaceutical Companies of Johnson and Johnson, 2301 CA Leiden, The Netherlands
Author to whom correspondence should be addressed.
Biomedicines 2018, 6(3), 81;
Received: 29 June 2018 / Revised: 20 July 2018 / Accepted: 23 July 2018 / Published: 26 July 2018
(This article belongs to the Special Issue Adenoviruses: From Virus to Medicine)
PDF [1019 KB, uploaded 26 July 2018]


Adenoviral vectored vaccines against infectious diseases are currently in clinical trials due to their capacity to induce potent antigen-specific B- and T-cell immune responses. Heterologous prime-boost vaccination with adenoviral vector and, for example, adjuvanted protein-based vaccines can further enhance antigen-specific immune responses. Although leading to potent immune responses, these heterologous prime-boost regimens may be complex and impact manufacturing costs limiting efficient implementation. Typically, adenoviral vectors are engineered to genetically encode a transgene in the E1 region and utilize the host cell machinery to express the encoded antigen and thereby induce immune responses. Similarly, adenoviral vectors can be engineered to display foreign immunogenic peptides on the capsid-surface by insertion of antigens in capsid proteins hexon, fiber and protein IX. The ability to use adenoviral vectors as antigen-display particles, with or without using the genetic vaccine function, greatly increases the versatility of the adenoviral vector for vaccine development. This review describes the application of adenoviral capsid antigen-display vaccine vectors by focusing on their distinct advantages and possible limitations in vaccine development. View Full-Text
Keywords: adenovirus; vaccine; adenovirus vector; capsid; capsid-display; hexon; fiber; penton; pIX adenovirus; vaccine; adenovirus vector; capsid; capsid-display; hexon; fiber; penton; pIX

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Vujadinovic, M.; Vellinga, J. Progress in Adenoviral Capsid-Display Vaccines. Biomedicines 2018, 6, 81.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top